Lamivudine monoprophylaxis for liver transplant recipients with non-replicating hepatitis B virus infection
Version of Record online: 18 JAN 2007
Volume 21, Issue 2, pages 166–171, March/April 2007
How to Cite
Yoshida, H., Kato, T., Levi, D. M., Regev, A., Madariaga, J. R., Nishida, S., Martinez, E. J., Schiff, E. R., Omata, M. and Tzakis, A. G. (2007), Lamivudine monoprophylaxis for liver transplant recipients with non-replicating hepatitis B virus infection. Clinical Transplantation, 21: 166–171. doi: 10.1111/j.1399-0012.2006.00557.x
- Issue online: 10 APR 2007
- Version of Record online: 18 JAN 2007
- Accepted for publication 9 June 2006
- hepatitis B immunoglobulin;
- hepatitis B virus;
- liver transplantation
Abstract: Background: The aim of this study was to evaluate the efficacy of lamivudine (LAM) monoprophylaxis for patients with non-replicating hepatitis B virus (HBV) infection at orthotopic liver transplantation (OLT).
Methods: Among 128 liver recipients with HBV infection between 1994 and 2004 transplanted at our institution, 60 had non-replicating HBV infection at the time of OLT. Of those, 26 patients received LAM prophylaxis (monoprophylaxis group) and 34 patients received LAM and hepatitis B immunoglobulin (HBIG) prophylaxis (combination group) after OLT.
Results: Median follow-up after OLT was 67 and 54 months, for monoprophylaxis and combination groups respectively. One and five yr patient/graft survival were 96/85% and 96/80% in monoprophylaxis group, and 85/79% and 67/55% in combination group. HBV DNA was re-detected or increased >105 IU/mL in four patients (15%) at 20–29 month in monoprophylaxis group and six (18%) at 4–35 months in combination group. Recurrent hepatitis was seen in two patients (8%) at 27 and 45 months and monoprophylaxis group and three (9%) at 21–35 months in combination group. The rate of recurrence was not statistically different between two groups.
Conclusion: LAM monoprophylaxis seemed to be effective for OLT recipients with HBV infection who had non-replicating HBV at transplantation. HBIG administration may play a less valuable role in preventing HBV recurrence in this group of patients.